Blood Test Identifies Dementia Risk in Women 25 Years Before Symptoms Emerge

A landmark study from UC San Diego has demonstrated that a single blood draw can identify women at elevated risk for dementia up to 25 years before cognitive symptoms emerge. The research, which tracked nearly 3,000 women over decades, marks the longest prospective validation of a blood-based Alzheimer's biomarker ever conducted — and arrives at a pivotal moment when the first FDA-cleared blood tests for Alzheimer's disease are entering clinical practice. But the finding also raises urgent questions about what to do with that knowledge, particularly for the millions of women who bear a disproportionate burden of the disease.

The Study: 25 Years of Data, One Revealing Protein

Published March 10, 2026 in JAMA Network Open, the study drew on stored blood samples from 2,766 participants in the Women's Health Initiative Memory Study (WHIMS), a landmark national study that enrolled women ages 65 to 79 in the late 1990s and tracked their cognitive health for up to a quarter-century [1][2].

The researchers measured levels of phosphorylated tau 217 (p-tau217), a protein that accumulates in the blood as toxic tau tangles — a hallmark of Alzheimer's disease — build up in the brain. All participants were cognitively unimpaired when their blood was drawn. Over the following decades, 1,311 of them developed mild cognitive impairment (MCI) or dementia [3].

The results were striking. Women with the highest levels of p-tau217 at baseline faced approximately seven times the risk of developing dementia compared to those with the lowest levels. Even moderately elevated levels were associated with more than three times greater risk [3].

"Our study suggests we may be able to identify women at elevated risk for dementia decades before symptoms emerge," said Dr. Aladdin H. Shadyab, the study's first author and an associate professor at UC San Diego. "That kind of long lead time opens the door to earlier prevention strategies and more targeted monitoring, rather than waiting until memory problems are already affecting daily life" [1].

Not All Women Face Equal Risk

The association between p-tau217 and dementia was not uniform. The study identified several factors that modified the biomarker's predictive power:

Age at testing played a significant role. Women over 70 at baseline showed a stronger link between elevated p-tau217 and subsequent cognitive decline than those in their late 60s [1][2].

Genetics mattered too. Carriers of the APOE ε4 allele — the most well-established genetic risk factor for late-onset Alzheimer's — showed a markedly stronger correlation between the blood protein and future dementia [1].

Hormone therapy emerged as an unexpected modifier. Women who had been randomized to estrogen-plus-progestin hormone therapy displayed a stronger association between p-tau217 and dementia risk than those on placebo, a finding that may reignite debate about the complex relationship between hormone replacement and brain health [1][3].

Race also influenced results. The connection between p-tau217 and dementia was stronger in white women than in Black women when measured alone. However, when researchers combined the biomarker with age, the predictive accuracy improved similarly across both racial groups — a critical finding for ensuring any future clinical tool works equitably [1][3].

"Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests," noted Dr. Linda K. McEvoy, the study's senior author at Kaiser Permanente Washington Health Research Institute [3].

Why Women Bear the Brunt of Alzheimer's Disease

The study's exclusive focus on women is no accident. Alzheimer's disease disproportionately affects women in ways that go far beyond simple longevity differences.

Nearly two-thirds of Americans living with Alzheimer's are women, according to the Alzheimer's Association. An estimated 7.2 million Americans age 65 and older are living with the disease in 2025, and that number is projected to climb to 12.7 million by 2050 [4]. Women are also roughly twice as likely to develop Alzheimer's as men, a disparity that has driven a growing field of sex-specific dementia research [5].

While women's greater average lifespan is part of the explanation — age remains the strongest risk factor for Alzheimer's — it is not the whole story. Research published in Nature Medicine in 2025 found that even after controlling for age, women face elevated risk, pointing to biological mechanisms including hormonal changes during menopause, sex differences in the APOE ε4 gene's effect, and distinct neuroinflammatory responses [5].

Early menopause — whether natural or surgically induced — before age 45 has been linked to increased risk of mild cognitive impairment and dementia. Estrogen is believed to exert protective effects on brain health, including blocking some of the harmful effects of amyloid-beta, the protein that forms plaques in Alzheimer's patients' brains. The precipitous drop in estrogen at menopause may therefore represent a critical vulnerability window [6].

The caregiving burden compounds the problem. Roughly two-thirds of unpaid dementia caregivers are women, and nearly 12 million Americans provide unpaid care to people with Alzheimer's and other dementias — contributing over 19 billion hours annually, valued at $413.5 billion [4].

The Blood Test Revolution: From Lab to Clinic

The WHIMS study arrives in a rapidly shifting landscape for Alzheimer's diagnostics. In May 2025, the FDA cleared the first-ever blood test for diagnosing Alzheimer's disease — the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, manufactured by Fujirebio — for use in symptomatic patients aged 55 and older. In clinical studies, 91.7% of positive results were confirmed by amyloid PET scans or cerebrospinal fluid testing, and 97.3% of negative results correctly ruled out amyloid pathology [7][8].

A second test, Roche's Elecsys pTau181, was subsequently cleared for primary care settings to rule out amyloid pathology — a significant step toward making blood-based Alzheimer's screening accessible beyond specialist clinics [9].

These tests currently cost approximately $195 out of pocket, though insurance coverage has been inconsistent. Medicare reimbursement codes are expected to be finalized by early 2026, which could dramatically expand access [10].

But there is a crucial distinction between these FDA-cleared tests and the new WHIMS findings. The approved tests are designed for people already showing symptoms of cognitive impairment. The new research suggests p-tau217 could potentially identify risk in cognitively healthy individuals — a fundamentally different and far more controversial application.

Source: GDELT Project

Data as of Mar 12, 2026CSV

The Biomarker Ecosystem: More Than One Protein

P-tau217 is the standout performer, but it is part of a growing arsenal of blood-based biomarkers for neurodegeneration. Understanding the full landscape is important for contextualizing this breakthrough.

P-tau217 reflects tau pathology — the toxic tangles of tau protein that are a defining feature of Alzheimer's disease. It has consistently shown the highest accuracy for detecting Alzheimer's-specific changes, with studies demonstrating 93-96% diagnostic accuracy for distinguishing Alzheimer's from other causes of dementia [11].

GFAP (Glial Fibrillary Acidic Protein) measures reactive astrocytosis — the brain's inflammatory response to early amyloid accumulation. Research has shown that blood GFAP levels are elevated at least 10 years before Alzheimer's symptoms appear, and notably, baseline GFAP tends to be higher in women, with stronger predictive effects in females [12][13].

NfL (Neurofilament Light Chain) is a marker of general neuronal damage, not specific to Alzheimer's. While elevated NfL predicts cognitive decline, it shows a weaker link to the specific amyloid and tau pathology that defines Alzheimer's disease [11].

A 2025 study in Alzheimer's & Dementia confirmed that combining these biomarkers — particularly p-tau217, GFAP, and NfL — provides the most robust stratification of disease stages, from preclinical through dementia [11].

The Treatment Gap: Can Early Detection Save Brains?

The most consequential question raised by this research is whether identifying at-risk women decades early can actually change outcomes. Currently, the answer remains uncertain.

Two FDA-approved disease-modifying treatments now exist. Lecanemab (Leqembi), approved in 2023, slowed cognitive decline by 27% over 18 months in a phase 3 trial of patients with early Alzheimer's disease [14]. Donanemab (Kisunla), approved in 2024, targets amyloid plaques through a different mechanism. Both drugs carry significant risks: the chance of amyloid-related imaging abnormalities (ARIA) — brain swelling or micro-bleeds — is 4.35 times higher than with placebo [15].

Critically, both drugs are indicated for patients who already have evidence of amyloid pathology and early symptoms. Two major prevention trials — the AHEAD study testing lecanemab and the TRAILBLAZER-ALZ 3 trial testing donanemab — are now investigating whether treating amyloid accumulation before symptoms emerge can prevent or delay Alzheimer's disease altogether [14].

If those prevention trials succeed, the WHIMS findings could transform clinical practice by identifying who should receive such interventions. If they fail, the ethics of widespread preclinical screening become far murkier.

The Economic and Human Stakes

The financial burden of Alzheimer's is staggering and growing. Health and long-term care costs are projected to reach $384 billion in 2025 alone, with a trajectory toward nearly $1 trillion by 2050. The lifetime cost of care per person averages approximately $405,262 [4].

One in three older Americans dies with Alzheimer's or another dementia, and deaths from the disease more than doubled between 2000 and 2022 [4]. The global picture is equally alarming: the prevalence of Alzheimer's disease and other dementias among adults 65 and older increased by 160% between 1991 and 2021, rising from 18.7 million to 49 million worldwide [16].

Early detection through blood testing could theoretically reduce these costs by enabling interventions before extensive brain damage occurs — or by helping families plan financially and legally while the patient can still participate in decisions. But it could also increase costs if screening identifies millions of at-risk individuals for whom no effective prevention exists.

Ethical Terrain: The Right to Know — and Not to Know

The prospect of telling a cognitively healthy 65-year-old woman that she has a sevenfold elevated risk of developing dementia raises profound ethical questions that the medical community is only beginning to address.

Psychological harm is a real concern. Knowledge of elevated risk without available prevention could cause anxiety, depression, or existential dread. Studies of genetic testing for Huntington's disease — where a positive result guarantees future illness — have shown significant psychological impact on some recipients.

Insurance and employment discrimination represent practical risks. While the Genetic Information Nondiscrimination Act (GINA) protects against genetic-based discrimination, it does not cover life insurance, disability insurance, or long-term care insurance — the very products most relevant to someone facing potential dementia.

Health equity concerns persist. If blood tests become clinical tools, will they be equally accessible to underserved communities? The WHIMS study's finding that p-tau217 alone was less predictive in Black women underscores the need for diverse validation before any screening program is implemented.

The study authors themselves urge caution. "Currently, blood-based biomarkers are not recommended for clinical use in people without symptoms of cognitive impairment," the paper notes. "Additional studies are needed to determine how p-tau217 testing might be used in routine clinical care and whether early identification can meaningfully change outcomes" [1].

What Comes Next

The WHIMS study represents the most compelling evidence yet that blood-based biomarkers can detect Alzheimer's risk decades before symptoms emerge in women. But translating that finding into clinical practice requires answering several outstanding questions:

• Validation in broader populations: The study included only women, and its racial diversity, while notable for such a long-running study, was limited. Replication in men and in more diverse cohorts is essential.
• Threshold determination: What level of p-tau217 should trigger concern, monitoring, or intervention? The study demonstrated a dose-response relationship but did not establish clinical cutoffs for screening.
• Intervention effectiveness: Until prevention trials report results, the clinical utility of preclinical screening remains theoretical.
• Integration with existing tests: How should p-tau217 results in asymptomatic individuals be interpreted alongside the FDA-cleared diagnostic tests designed for symptomatic patients?

The science of Alzheimer's blood testing has advanced with remarkable speed — from research curiosity to FDA-cleared diagnostics in just a few years. The WHIMS study pushes the frontier further, into the territory of presymptomatic prediction across decades. Whether medicine and society are ready to act on that knowledge is the question that now demands an answer.